A novel IncRNA TCLInc1 promotes peripheral T cell lymphoma progression through acting as a modular scaffold of HNRNPD and YBX1 complexes

Ping Zhao1,2, Meng-Meng Ji1, Ying Fang1, Xiao Li1, Hong-Mei Yi2, Zi-Xun Yan1, Shu Cheng1, Peng-Peng Xu1, Anne Janin3,4, Chao-Fu Wang2, Li Wang1,3 and Wei-Li Zhao1,3

Abstract
Long noncoding RNAs (lncRNAs) play an essential role in tumor progression. Few researches focused on the clinical and biological relevance of lncRNAs in peripheral T cell lymphoma (PTCL). In this research, a novel lncRNA (ENST00000503502) was identified overexpressed in the main subtypes of PTCL, and designated as T cell lymphoma-associated IncRNA1 (TCLInc1). Serum TCLInc1 was associated with extranodal involvement, high-risk International Prognostic Index, and poor prognosis of the patients. Both in vitro and in vivo, overexpression of TCLInc1 promoted T-lymphoma cell proliferation and migration, both of which were counteracted by the knockdown of TCLInc1 using small interfering RNAs. As the mechanism of action, TCLInc1 directly interacted with transcription activator heterogeneous nuclear ribonucleoprotein D (HNRNPD) and Y-box binding protein-1 (YBX1) by acting as a modular scaffold. TCLInc1/HNRNPD/YBX1 complex upregulated transcription of TGFB2 and TGFBR1 genes, activated the tumor growth factor-β signaling pathway, resulting in lymphoma progression, and might be a potential target in PTCL.

Introduction
Peripheral T cell lymphomas (PTCL) encompass a heterogeneous group of neoplasm derived from T cell lineages and represent ~10–15% of non-Hodgkin lymphoma1, mainly including anaplastic large-cell lymphoma (ALCL)-anaplastic lymphoma kinase (ALK)-positive (ALK+ ALCL), ALCL-ALK-negative (ALK− ALCL), angioimmunoblastic T cell lymphoma (AITL), and PRCL-not otherwise specified (PTCL-NOS)2. PTCLs are characterized by advanced disease stage at diagnosis3, and dismal prognosis, with a 5-year patients survival rate of <30% (except for ALK+ ALCL)4–6. Therefore, prognostic biomarkers closely related to lymphoma progression and expressed generally in the main histological subtypes need to be further investigated in PTCL.

To date, studies have focused on the alterations in protein-coding genes that serve as diagnostic and therapeutic targets of PTCL7. Growing evidence suggests that noncoding RNAs are also critically involved in tumor progression8,9. Long noncoding RNAs (lncRNAs) belong to a class of noncoding sequences >200 nucleotides in length10 and are emerging as essential factors in the tumorigenesis and metastasis of various cancers, including hematological malignancies11,12. The expression of HOTAIR enhances B-lymphoma cell growth through mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase signaling pathway13. LncRNA metastasis-associated lung adenocarcinoma transcript 1 is also overexpressed in hematological
malignancies\textsuperscript{14}, rendering tumor cell resistant to chemotherapeutic agents\textsuperscript{15}. As a mechanism of action, IncRNAs exhibit diverse aspects regarding tumor progression through regulating chromatin organization and gene transcription in the nucleus. IncRNAs also modulate messenger RNA (mRNA) stability, translation, and post-translational modification in the cytoplasm\textsuperscript{16,17}. However, pathogenic role and underlying molecular mechanism of IncRNAs remain largely unknown in vivo.

In the present study, we performed genome-wide IncRNA expression assay in PTCL and identified a novel IncRNA (ENST00000503502) associated with lymphoma progression and poor prognosis in patients, designating it as T cell lymphoma-associated IncRNA1 (TCLlnc1). The biological function of TCLlnc1 on T-lymphoma cell proliferation and migration was evaluated in vitro and in vivo.

Materials and methods

Patients and clinical specimens

Patients with newly diagnosed, histologically confirmed PTCL treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based chemotherapy between June 2013 and October 2019 were eligible and enrolled in this study. Exclusion criteria of patients were as previously described\textsuperscript{18}. One hundred and thirty-eight patients were included and their characteristics were summarized in Supplementary Table 1. The study was approved by the Shanghai Ruijin Hospital Review Board with informed consent obtained from all patients in accordance with the Declaration of Helsinki. Pathological diagnosis was established according to the World Health Organization classification\textsuperscript{19}.

Transcriptomic sequencing

Total RNA was extracted from high-quality frozen tumor samples of 40 PTCL cases (from 70 PTCL cases detected for TCLlnc1 levels) using RNA RNeasy Mini Kit (Qiagen, Dusseldorf, German) for RNA sequencing (RNA-seq) and analyzed as previously described\textsuperscript{20–25}.

Cell lines and culture conditions

T-leukemia/lymphoma cell lines Jurkat, Hut78, and embryonic kidney cell line HEK-293T were obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured as previously described\textsuperscript{26}.

Cell cycle assay

Jurkat and Hut78 cells were transfected with TCLlnc1 plasmid or small interfering RNA (siRNA). A total of 1 × 10\textsuperscript{6} Jurkat and Hut78 cells were harvested after 72 h of incubation, stained with propidium iodide (MultiSciences Biotech, Hangzhou, China), and analyzed by flow cytometry\textsuperscript{26}.

Cell proliferation assay

A total of 5 × 10\textsuperscript{3} Jurkat and Hut78 cells were seeded onto 96-well plates per well. After incubation for the indicated time (0, 24, 48, and 72 h), proliferation was measured using Cell Counting Kit-8 (Dojindo, Japan) according to the manufacturer’s protocol\textsuperscript{27}.

Transwell assay

Transwell assay was performed as previously described\textsuperscript{28}, the migrated cells in the lower compartments were counted by flow cytometry, and images of the cells fixed on the bottom surface of the filter were taken under the microscope.

Quantitative real-time PCR

RNA expression levels were measured using quantitative real-time polymerase chain reaction (qRT-PCR) as previously described\textsuperscript{26}. Glyceraldehyde-3-phosphate dehydrogenase (\textit{GAPDH}) was used as an endogenous control and Hut78 cells for calibration\textsuperscript{29–31}. The primers (Supplementary Table 2) were provided by Biosune Biotechnology Company (Shanghai, China).

Western blot

Western blot analysis was performed as previously described\textsuperscript{32}. Rabbit anti-heterogeneous nuclear ribonucleoprotein D (HNRPD) antibody (12382S, Cell Signaling Technology, Danvers, MA, USA) and rabbit anti-Y-box binding protein-1 (YBX1) (9744S, Cell Signaling Technology) antibody were used for western blot. The dilution of primary antibodies was 1:1000. An anti-GAPDH antibody was used as the endogenous loading control.

Fluorescence in situ hybridization (FISH)

The expression of TCLlnc1 in Jurkat cells was examined by using in situ hybridization assay\textsuperscript{33}, with anti-TCLlnc1 oligodeoxynucleotide probe sets (IncRNA FISH Probe Mix, Sangon Biotech, Shanghai, China).

In vitro transcription

Full length of TCLlnc1 and antisense TCLlnc1 were cloned from the plasmid of TCLlnc1 into downstream of the T7 promoter using Phanta EVO HS Super-Fidelity DNA Polymerase (Vazyme, Nanjing, China). TCLlnc1 and antisense TCLlnc1 with T7 promoter was purified with Wizard\textsuperscript{™} SV Gel and PCR Clean-Up System (Promega, Madison, WI, USA). In vitro transcription assays were performed using MEGAscript\textsuperscript{™} T7 Transcription Kit according to the manufacturer’s instructions (Invitrogen).

RNA pull-down assay

RNA pull-down assays were performed with Pierce\textsuperscript{™} Magnetic RNA-Protein Pull-Down Kit (Thermo) according to the manufacturer’s instructions\textsuperscript{34}.
RNA immunoprecipitation

RNA immunoprecipitation (RIP) experiments were performed using the Magna RIPTM Kit (Millipore, Billerica, MA, USA). The co-precipitated RNAs were detected by RT-PCR. To demonstrate that the detected RNA signals specifically bind to either HNRNP D or YBX1, the total RNA (input controls) and normal rabbit IgG controls were simultaneously assayed.

Plasmids, lentivirus construction, and small interfering RNAs

Full-length TCLlnc1 was cloned into the vector pLenti CMV-MCS-EF1α-ZsGreen1-PGK-Puro for over-expression (Lingke Biotech, Shanghai, China). All short hairpin RNA (shRNA) lentivirus and siRNAs involved in expression (Lingke Biotech, Shanghai, China). All siRNA sequences are provided in Supplementary Table 3.

Co-immunoprecipitation (Co-IP)

Manual immunoprecipitation was performed according to Pierce™ Classic Magnetic IP/Co-IP Kit User Guide (Thermo). Both the input and co-IP samples were analyzed by western blot analysis using anti-HNRNP D or anti-YBX1 antibodies (Cell Signaling Technology).

Luciferase reporter assay

The designated combinations of indicated plasmids and other relevant siRNAs plus pRL-TK-Renilla were transfected into HEK-293T cells with the Lipofectamine 3000 reagent (Invitrogen), and luciferase activity was detected using the Dual-Luciferase Reporter Assay System (Promega).

In vivo experiments

Female BALB/c nude mice 5 to 6 weeks of age were purchased from the Shanghai Laboratory Animal Center (Shanghai, China). All experiments were performed in accordance with relevant institutional and national guidelines and the regulations of the Shanghai Medical Experimental Animal Care Commission. The subject was approved by the Laboratory Animal Ethics Committee of Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine. In vivo experiments were performed as previously described26.

Statistical analysis

All statistical analyses were performed using SPSS 21.0 (IBM, Armonk, NY, USA). The significance of the differences between groups was estimated using either the Student’s t test, χ² test, or Mann–Whitney U test. Progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan–Meier method with the log-rank test for comparisons. The Cox regression and proportional hazards models were used for univariate/multivariate analysis. A value of P < 0.05 indicated a significant difference.

Results
LnRNA candidate ENST0000053502 is clinically relevant in PTCL

LnRNA expression profile was examined in tissue samples of ten PTCL and ten reactive hyperplasia (RH) using Arraystar Human LncRNA Microarray v2.0. In total, 33,045 IncRNAs and 30,215 mRNAs were collected from the authoritative databases RefSeq, UCSC Known Genes dataset, Ensembl, and related literatures, as per the manufacturer’s instructions. Heatmap displayed differentially expressed IncRNAs and mRNAs in PTCL, as compared to RH (Fig. 1A). To identify potential oncogenic IncRNAs, more stringent filtering criteria (raw signal intensity >2000, fold change >2, P < 0.01, 200 nt < RNA length <1000 nt, Fig. 1B) were used and 54 upregulated IncRNAs were obtained; IncRNA-mRNA co-expression network analysis was performed using the Cytoscape software. The top five IncRNAs (ENST00000394174, ENST00000432567, ENST0000053502, ENST00000456305, and NR_033390) with more co-expressed oncogenes (according to the Catalogue Of Somatic Mutations In Cancer [COSMIC, https://cancer.sanger.ac.uk] database) in PTCL than in RH were identified as candidate IncRNAs and assessed by qRT-PCR (Supplementary Fig. 1A). As shown in Supplementary Fig. 1B, ENST0000053502 expression level was significantly higher in PTCL tissues compared with RH tissues (P = 0.0004). Thus, among the candidate IncRNAs, ENST0000053502 presented a significant increase in PTCL and had the strongest correlation with the expression of oncogenes, which mainly involved in the cell cycle, cytokine-related pathways, metastasis, and chemotherapy resistance (Fig. 1C); thereby, ENST0000053502 was designated TCLlnc1, and further exploration of clinical significance and biological functions should be explored. TCLlnc1 was located in chromosome 4 (chr4:139,546,266–139,546,727) with a 462 nt length and identified as an IncRNA rather than a protein-coding transcript by CPC (Coding Potential Calculator, http://cpc.cbi.pku.edu.cn). An analysis was performed on the coding potential using CPAT (Coding Potential Assessment Tool, http://lilab.research.bcm.edu/cpat), and the results indicated that TCLlnc1 was unlikely to encode any protein product (Supplementary Fig. 1C).

In order to validate the microarray data, TCLlnc1 expression was detected by qRT-PCR in tumor samples of 70 PTCL patients, including 9 cases of ALK+ALCL, 6 cases of ALK ALCL, 23 cases of AITL, and 32 cases of PTCL-NOS, as well as 16 cases of RH. Compared with RH (0.224 ± 0.101), the expression level of TCLlnc1 was significantly increased in the main subtypes of PTCL (ALK+ALCL, 2.075 ± 0.682, P = 0.0005, AITL, 0.982 ± 0.379, P =
0.0005, and PTCL-NOS, 1.386 ± 0.365, \( P = 0.0002 \), Fig. 2A). Moreover, the expression of TCLlnc1 in serum positively correlated with TCLlnc1 in tumors of PTCL patients (\( P < 0.0001 \), Fig. 2B). TCLlnc1 expression was then assessed in enlarged serum samples of 138 PTCL patients, including 18 cases of ALK\(^+\)ALCL, 12 cases of ALK\(^-\)ALCL, 53 cases of AITL, and 55 cases of PTCL-NOS, as well as in 10 cases of RH and 10 cases of healthy volunteers (HVs). Serum TCLlnc1 was significantly higher in PTCL patients (ALK\(^+\)ALCL, 0.651 ± 0.134, \( P < 0.0001 \), ALK\(^-\)ALCL, 3.940 ± 1.625, \( P < 0.0001 \), AITL, 1.879 ± 0.335, \( P < 0.0001 \), and PTCL-NOS, 2.986 ± 0.457, \( P < 0.0001 \) than in HV (0.076 ± 0.030), no significant difference was observed between RH and HV (\( P = 0.5288 \), Fig. 2C).

As shown in Table 1, 138 PTCL patients were divided into high- and low-expression groups based on the median value of TCLlnc1. High TCLlnc1 expression group was significantly associated with extranodal involvement (\( P = 0.0152 \), high-risk International Prognostic Index (IPI) (\( P = 0.0063 \), and poor chemotherapy
Fig. 2 TCL1nc1 was clinically relevant in PTCL. A: Expression of TCL1nc1 in tumors of anaplastic large-cell lymphoma (ALCL)-anaplastic lymphoma kinase (ALK)-positive (ALK+ALCL, n = 9), ALCL-ALK negative (ALK-ALCL, n = 6), angioimmunoblastic T cell lymphoma (AITL, n = 23), and peripheral T cell lymphoma-not otherwise specified (PTCL-NOS, n = 32), as compared to RH (n = 16) by quantitative real-time polymerase chain reaction (qRT-PCR). B: Correlation between TCL1nc1 expression in tumor and in serum of PTCL patients (n = 70). C: Expression of TCL1nc1 in serum of RH (n = 10), ALK+ALCL (n = 18), ALK-ALCL (n = 12), AITL (n = 53), and PTCL-NOS (n = 55) in comparison with healthy volunteers (HV, n = 10). TCL1nc1 expression was quantified by qRT-PCR. D, E: Progression-free survival (PFS, D) and overall survival (OS, E) of PTCL patients according to TCL1nc1 expression in serum (n = 138). F, G: Univariate and multivariate analysis for PFS (F) and OS (G) in PTCL (n = 138).
Table 1  Clinicopathological characteristics of PTCL patients according to TCLinc1 expression in serum (n = 138)*.

| Variables               | Low TCLinc1 (n = 69) | High TCLinc1 (n = 69) | P value |
|-------------------------|----------------------|-----------------------|---------|
| Gender                  |                      |                       | 0.4650  |
| Female                  | 20 (29%)             | 24 (35%)              |         |
| Male                    | 49 (71%)             | 45 (65%)              |         |
| Age (years)             |                      |                       | 0.1677  |
| <60                     | 44 (64%)             | 36 (52%)              |         |
| ≥60                     | 25 (36%)             | 33 (48%)              |         |
| ECOG                    |                      |                       | 0.8127  |
| 0–1                     | 58 (84%)             | 59 (86%)              |         |
| ≥2                      | 11 (16%)             | 10 (14%)              |         |
| LDH level               |                      |                       | 0.4823  |
| Normal                  | 24 (35%)             | 28 (41%)              |         |
| Elevated                | 45 (65%)             | 41 (59%)              |         |
| Extranodal involvement  |                      |                       | 0.0152  |
| <2                      | 48 (70%)             | 34 (49%)              |         |
| ≥2                      | 21 (30%)             | 35 (51%)              |         |
| Ann Arbor stage         |                      |                       | 0.2359  |
| I–II                    | 20 (29%)             | 14 (20%)              |         |
| III–IV                  | 49 (71%)             | 55 (80%)              |         |
| IPI                     |                      |                       | 0.0063  |
| Low risk                | 45 (65%)             | 29 (42%)              |         |
| High risk               | 24 (35%)             | 40 (58%)              |         |
| Response to treatment   |                      |                       | 0.0006  |
| CR                      | 41 (59%)             | 21 (30%)              |         |
| Non-CR                  | 28 (41%)             | 48 (70%)              |         |

*ECOG Eastern Cooperative Oncology Group, LDH lactic dehydrogenase, IPI International Prognostic Index, CR complete remission.

χ² test.

response (P = 0.0006). Accordingly, median PFS and OS of the patients in the high TCLinc1 expression group were 10 and 20 months, respectively; significantly shorter than those of the low TCLinc1 expression group (34 months, P = 0.0003, Fig. 2D, and not arrived, P < 0.0001, respectively, Fig. 2E). Univariate analysis showed that multiple extranodal involvements, advanced stage, and high levels of serum TCLinc1 were adverse prognostic factors for both PFS and OS. When using multivariate analysis, high level of serum TCLinc1 and advanced stage were independent adverse prognostic factors for both PFS and OS (Fig. 2F, G).

TCLinc1 promotes T-lymphoma cell proliferation and migration in vitro

To further determine the biological function of TCLinc1 in PTCL, overexpression and knockdown of TCLinc1 were performed using TCLinc1 plasmid and siRNA on T-lymphoma cell line Jurkat and Hut78. The expression level of TCLinc1 was measured by qRT-PCR, and Jurkat cells expressed a higher level of TCLinc1 than those of Hut78 cells (0.076 ± 0.004 vs. 0.033 ± 0.003, P = 0.0013, Fig. 3A). Jurkat and Hut78 cells transfected with TCLinc1 plasmid showed higher expression levels of TCLinc1 than cells transfected with vectors (Jurkat: 0.401 ± 0.090 vs. 0.076 ± 0.004, P = 0.0230, Fig. 3B; Hut78: 0.474 ± 0.038 vs. 0.033 ± 0.003, P = 0.0003, Supplementary Fig. 2A). After a 72-h culture, overexpression of TCLinc1 significantly increased cell proliferation, as compared to vector cells (Jurkat: 1.471 ± 0.085 vs. 0.927 ± 0.150, P = 0.0341, Fig. 3C; Hut78: 2.230 ± 0.042 vs. 1.602 ± 0.136, P = 0.0116, Supplementary Fig. 2B). Flow cytometric analysis revealed that TCLinc1 decreased tumor cell arrest in the G0/G1 phase (Jurkat, TCLinc1 vs. control vector: 41.240 ± 0.413% vs. 46.980 ± 0.927%, P = 0.0048; Hut78, TCLinc1 vs. control vector: 22.810 ± 0.550% vs. 31.170 ± 0.260%, P = 0.0002), with an obvious increase in S-phase cells (Jurkat, TCLinc1 vs. control vector: 46.350 ± 1.524% vs. 40.000 ± 1.176%, P = 0.0299, Fig. 3D; Hut78, TCLinc1 vs. control vector: 51.250 ± 1.407% vs. 46.260% ± 0.806%, P = 0.0372, Supplementary Fig. 2C). Meanwhile, overexpression of TCLinc1 significantly promoted cell migration, as compared to vector cells (Jurkat: 1.831% vs. 43.610% ± 1.717%, P = 0.0203, Supplementary Fig. 2D; Hut78: 2.230 ± 0.042 vs. 1.845 ± 0.058, P = 0.005 ± 0.001, Fig. 3F; Hut78, 0.005 ± 0.001 vs. 0.014 ± 0.001, P = 0.0001, Supplementary Fig. 2E). Knockdown of TCLinc1 significantly reduced cell proliferation (Jurkat, 0.927 ± 0.076 vs. 1.710 ± 0.104, P = 0.0036, Fig. 3G; Hut78, 1.320 ± 0.141 vs. 1.845 ± 0.058, P = 0.0261, Supplementary Fig. 2F), decreased S-phase cells (Jurkat, 25.200 ± 1.199% vs. 44.700 ± 3.794%, P = 0.0080, Fig. 3H; Hut78, 34.250 ± 1.831% vs. 43.610% ± 1.717%, P = 0.0203, Supplementary Fig. 2G) and retarded cell migration (Jurkat, 21,070 ± 8331 vs. 51,844 ± 6899, P = 0.0117, Fig. 3I; Hut78, 5647 ± 1150 vs. 13673 ± 2442, P = 0.0410, Supplementary Fig. 2H).

TCLinc1 promotes T-lymphoma cell proliferation in vivo

In order to search for in vivo evidence of TCLinc1 on lymphoma progression, murine xenograft models were established with subcutaneous injection of Jurkat cells stably transfected with pLenti-TCLinc1 or pLenti-Vector (as control), as well as pLenti-shRNA-TCLinc1 or pLenti-
Fig. 3 TCLinc1 promoted T-lymphoma cell proliferation and migration in vitro. A Expression of TCLinc1 in Jurkat and Hut78 cells by qRT-PCR. B Overexpression of TCLinc1 on Jurkat cells. C–E Effect of TCLinc1 overexpression on cell proliferation (C), cell cycle (D), and cell migration (E) of Jurkat cells. Representative fields in transwell assay were captured using an inverted microscope (left) and the total number of migrated cells in the lower compartments was counted by flow cytometry (right). The scale bar represents 100 μm. F Knockdown of TCLinc1 on Jurkat cells. G–I Effect of TCLinc1 knockdown on cell proliferation (G), cell cycle (H), and cell migration (I) of Jurkat cells. Representative fields in transwell assay were captured using an inverted microscope (left) and the total number of migrated cells in the lower compartments was counted by flow cytometry (right). The scale bar represents 100 μm.
shRNA-ct (as control). The sizes and weights of pLenti-TCLlnc1 tumors were significantly larger than those of pLenti-Vector tumors (Fig. 4A). Tumors of pLenti-TCLlnc1 exhibited increased positivity of Ki-67 (Fig. 4B). Accordingly, knockdown of TCLlnc1 reduced tumor growth, thus affecting the weight of pLenti-shRNA-TCLlnc1 tumors, as compared to pLenti-shRNA-ct tumors (Fig. 4C). Tumors of pLenti-shRNA-TCLlnc1 exhibited decreased positivity of Ki-67 (Fig. 4D).

**TCLlnc1 activates tumor growth factor (TGF-β) signaling and regulates cytokine production**

To better understand the underlying molecular mechanism of TCLlnc1, we performed RNA-seq analysis to obtain the transcriptional profiles in tumor samples of PTCL patients according to TCLlnc1 expression. Forty PTCL patients were divided into high- and low-expression groups based on the median value of TCLlnc1. A total of 1115 differentially expressed transcripts (fold change ≥ 1.5, P < 0.05) were identified; these included 372 upregulated and 743 downregulated transcripts (Fig. 5A). Gene ontology (GO) analysis showed that the most significantly altered biological processes included pathways involved in cytokine production, cell–cell adhesion, and cytokine secretion (Fig. 5B). Gene set enrichment analysis (GSEA) revealed that the gene sets were significantly related to regulation of tumor necrosis factor (TNF) biosynthetic process, cellular response to TGF-β stimulus, and...
regulation of epithelial to mesenchymal transition (Fig. 5C). Clinically, the correlation between the expression levels of TCLlnc1 and cytokines, such as interleukin-6 (IL-6), IL-10, and TNF in serum (Fig. 5D) of PTCL patients indicated that TCLlnc1 activated TGF-β signaling pathway and regulated cytokine production in PTCL.

TCLlnc1 interacts with HNRNPD and YBX1 as a modular scaffold

LncRNA exerts biological function by physically interacting with transcriptional factors, histone regulators, and other cellular factors. FISH assay showed that TCLlnc1 was mainly located in the nucleus of Jurkat cells (Fig. 6A), suggesting that TCLlnc1 may function at the transcriptional level via interacting with nucleus molecules or proteins. To further explore the underlying molecular mechanism, biotinylated TCLlnc1 and antisense TCLlnc1 RNA (negative control) were incubated with total protein extracts from Jurkat cells and pulled down with streptavidin. Only HNRNPD and YBX1 were detected by mass spectrometry from three independent RNA pull-down assays (Fig. 6B) and immunoblotting (Fig. 6C).
**Fig. 6** TCLlnc1 physically interacted with heterogeneous nuclear ribonucleoprotein D (HNRNPD) and Y-box binding protein-1 (YBX1).

**A** Nuclear location of TCLlnc1 in Jurkat cells (red). Nuclei were stained by 4′, 6-diamidino-2-phenylindole (DAPI, blue).

**B** TCClnc1-binding proteins detected by mass spectrometry.

**C** Western blot validation of proteins pulled down with TCLlnc1.

**D** Interaction of TCLlnc1 with HNRNPD and YBX1 detected by RNA immunoprecipitation (RIP) assay. The fold enrichment of TCLlnc1 in RIP is relative to its matching IgG control RIP. LncRNA linc00152 was referred as a negative control.

**E** Expression of TCLlnc1, HNRNPD, and YBX1 after indicated RNA knockdown detected by qRT-PCR and western blot.

**F** Western blot analysis of HNRNPD and YBX1 pulled down by full-length or truncated TCLlnc1.

**G** Interaction of HNRNPD and YBX1 after TCLlnc1 knockdown detected by co-immunoprecipitation (co-IP).
Physical interaction of TCLnc1 with HNRNPD and YBX1 was validated by RIP using anti-HNRNPD antibody and anti-YBX1 antibody, with linc00152 as a negative control. TCLnc1 is specifically bound to HNRNPD and YBX1 in Jurkat cells (Fig. 6D). In addition, qRT-PCR and western blot assays showed that knockdown of TCLnc1 had no effect on HNRNPD and YBX1 mRNA expression or protein expression. The knockdown of HNRNPD and YBX1 had no effect on TCLnc1 expression (Fig. 6E). These data indicated that TCLnc1 physically interacted with HNRNPD and YBX1. Subsequently, a series of TCLnc1 deletion mutants were constructed to map the precise binding regions for HNRNPD and YBX1. According to in vitro RNA pull-down assays, segment 1–324 nt of TCLnc1 interacted with HNRNPD, while segment 216–462 nt of TCLnc1 interacted with YBX1 (Fig. 6F). Moreover, as revealed by co-IP, HNRNPD, and YBX1 interacted with each other in Jurkat cells and could be attenuated by knockdown of TCLnc1 (Fig. 6G). Together, TCLnc1 was important for HNRNPD and YBX1 complex formation as a modular scaffold.

**TCLnc1 functions with HNRNPD and YBX1 complex in regulating TGF-β signaling pathway**

Because lncRNA regulates downstream genes expression by interacting with transcription factors, we next investigated which of the TGF-β signaling pathway genes are regulated by the TCLnc1, HNRNPD and YBX1 complex. As shown by qRT-PCR in Jurkat cells, the relative mRNA expression level of TGF-β2 (TGFB2) and TGF-β receptor I (TGFBRI) was significantly upregulated by overexpression of TCLnc1 (TGFB2: 1.004 ± 0.064 vs. 2.471 ± 0.350, \( P = 0.0146 \); TGFBRI: 1.039 ± 0.044 vs. 2.105 ± 0.323, \( P = 0.00316 \), HNRNPD (TGFB2: 1.004 ± 0.064 vs. 2.311 ± 0.229, \( P = 0.0054 \); TGFBRI: 1.049 ± 0.044 vs. 1.653 ± 0.061, \( P = 0.0013 \), and YBX1 (TGFB2: 1.004 ± 0.064 vs. 2.777 ± 0.240, \( P = 0.0020 \); TGFBRI: 1.049 ± 0.044 vs. 1.920 ± 0.087, \( P = 0.0009 \) (Fig. 7A), but was downregulated by knockdown of TCLnc1 (TGFB2: 1.004 ± 0.065 vs. 0.338 ± 0.093, \( P = 0.0042 \); TGFBRI: 1.000 ± 0.225 vs. 0.446 ± 0.060, \( P = 0.0010 \), HNRNPD (TGFB2: 1.004 ± 0.065 vs. 0.620 ± 0.023, \( P = 0.0051 \); TGFBRI: 1.000 ± 0.225 vs. 0.548 ± 0.016, \( P < 0.0001 \), and YBX1 (TGFB2: 1.004 ± 0.065 vs. 0.509 ± 0.034, \( P = 0.0025 \); TGFBRI: 1.000 ± 0.225 vs. 0.4777 ± 0.047, \( P = 0.0006 \) (Fig. 7B). Other key genes of TGF-β signaling pathway were not altered by TCLnc1, HNRNPD, or YBX1, such as TGF-β1 (TGFB1), TGF-β3 (TGFB3), TGF-β receptor II (TGFBRII), and SMAD2, SMAD3, SMAD4 (Supplementary Fig. 3A). qRT-PCR analysis of TGFB2 and TGFBRI expression was performed in the pLenti-Vector, pLenti-TCLnc1-, pLenti-shRNA-NC-, and pLenti-shRNA-TCLnc1-transfected Jurkat cells, revealing similar results in vivo (Supplementary Fig. 3B).

To finally confirm the direct regulation of TCLnc1/HNRNPD/YBX1 complex to TGFB2 and TGFBRI expression, luciferase assays were performed. As expected, HNRNPD and YBX1 activated TGFB2 and TGFBRI transcription by binding to the promoters of TGFB2 and TGFBRI (Fig. 7C). The knockdown of HNRNPD or YBX1 reversed TCLnc1-mediated cell proliferation (Fig. 7D) and migration (Fig. 7E). These data demonstrated that TCLnc1 exerted its function by binding to HNRNPD and YBX1. TCLnc1/HNRNPD/YBX1 complex regulated key gene transcription to activate TGF-β signaling pathway, induce cytokine production, and promote cell proliferation and invasion in PTCL (Fig. 7F).

**Discussion**

LncRNAs are aberrantly expressed in various cancers and actively participate in disease progression. In the present study, TCLnc1 was identified as a lncRNA overexpressed in the main PTCL histological subtypes linked to both lymphoma cell proliferation and in vitro and in vivo migration. Of note, circulating lncRNAs have potential utility as noninvasive and blood-based biomarkers. Accordingly, we revealed that serum TCLnc1 expression correlated with tumor TCLnc1 expression and was significantly associated with extranodal involvement, high-risk IPI, and independently indicated poor patients’ clinical outcomes. Therefore, not only do our findings support the essential role TCLnc1 plays during tumor progression, but we also provide a potential biomarker for PTCL disease prognosis prediction.

TGF-β signaling pathway represents one of the best-recognized cascades modulating tumor proliferation and migration. We showed that TCLnc1 overexpression led to the activation of TGF-β signaling pathway and production of cytokines, such as IL-6, IL-10, and TNF. The results are consistent with the previous study regarding cutaneous T cell lymphoma, stating that TGF-β and IL-10 are hallmarks of advanced stages, increased cell migration, and decreased antitumor responses. TGF-β is composed of three isoforms, TGFB1, TGFB2, and TGFB3. In order to activate the TGF-β signaling pathway, TGF-β isoforms bind to TGFBRII, thereby recruiting TGFBRI and upregulate downstream cascade. Here, TGFB2 and TGFBRI were potential targets of TGF-β signaling activation provoked by TCLnc1 overexpression. Galunieribib, a small-molecular inhibitor of TGFBRI, has recently been reported to possess efficient tumor inhibitory activity in breast cancer and multiple myeloma. Based on the fact that TCLnc1 promoted both tumor growth and the migration of PTCL via TGF-β signaling activation, therapeutic targeting of TGF-β may counteract tumor progression in PTCL with TCLnc1 overexpression.

LncRNAs interact with RNA-binding proteins to form nuclear ribonucleoprotein complexes, which are crucial...
**Fig. 7** TCLlnc1 provoked lymphoma progression via HNRNPD and YBX1. 

**A** Expression of TGFB2 and TGFBR1 after overexpression of TCLlnc1, HNRNPD, or YBX1 detected by qRT-PCR.

**B** Expression of TGFB2 and TGFBR1 after knockdown of TCLlnc1, HNRNPD, or YBX1 detected by qRT-PCR.

**C** Luciferase activity assay of TGFB2 and TGFBR1 promoter in cells transfected with HNRNPD siRNA, YBX1 siRNA, or NC siRNA.

**D** Proliferation of Jurkat cells after transfection of HNRNPD siRNA or the YBX1 siRNA, plasmid encoding TCLlnc1, or control vector.

**E** Migration of Jurkat cells after transfection of HNRNPD siRNA or the YBX1 siRNA, plasmid encoding TCLlnc1, or control vector.

**F** A schematic model of lncRNA TCLlnc1 function in PTCL.
regulators of transcriptional programs in the nucleus. Our results demonstrated that TCLlnc1 directly interacted with HNRNPD and YBX1 and acts as a modular scaffold in PTCL. HNRNPs represent an RNA-binding ribonucleoprotein family of transcription activators that are implicated in RNA stability and gene expression regulation in various cancers. In colorectal cancer, HNRNPD interacts with LINC01354 and contributes to proliferation and metastasis through the activation of the Wnt/β-catenin signaling pathway. YBX1 is also a transcription activator of the RNA- and DNA-binding domain. The RNA-binding domain can bind to lncRNA or mRNA, whereas the DNA-binding domain binds to a consensus sequence in the target genes promoter, implicating numerous cellular processes, particularly tumorigenesis. More importantly, in multiple cancer types, S-phase-enriched lncRNAs interact with HNRNP–YBX1 complex and affect cancer cell hallmarks through regulating phosphatidylinositol-3-kinase/AKT and MAPK signaling activation. Our findings indicated that HNRNPD and YBX1 are required for TCLlnc1-mediated regulation of TGF-β signaling pathway, as well as T-lymphoma cell proliferation and migration. The results further strengthen the understanding of lncRNA as an oncogenic driver on PTCL progression.

Conclusions

TCLlnc1 is a clinically, functionally, and mechanistically oncogenic lncRNA in PTCL. TCLlnc1 and its downstream signaling pathway may be meaningful for risk stratification and targeted therapy in patients with PTCL.

Acknowledgements

We appreciate the effort of the physicians in enrolling patients and thank all the patients involved for allowing us to analyze their clinical data.

Author details

P.Z. and M.-M.J. carried out the experiments and wrote the manuscript. Y.F. performed qRT-PCR and analyzed data. X.L. and Z.-X.Y. prepared biological samples. S.C., P.-P.X., and A.J. gathered detailed clinical information for the study and analyzed the data. H.-M.Y. and C.-F.W. performed pathological samples. S.C., P.-P.X., and A.J. gathered detailed clinical information for the study and analyzed the data. X.L. and Z.-X.Y. prepared biological samples. P.Z. and M.-M.J. carried out the experiments and wrote the manuscript. All authors read and approved the final manuscript.

Funding

This study was supported, in part, by research funding from the National Natural Science Foundation of China (81670716, 81520108003, and 81830007); the Chang Jiang Scholars Program; the Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant Support (20152206 and 20152208); Clinical Research Plan of Shanghai Hospital Development Center (SHDC2020CR1032B); Shanghai Science and Technology Development fund (19MC1911000); the Multicenter Clinical Research Project by Shanghai Jiao Tong University School of Medicine (DLY201601); the Collaborative Innovation Center of Systems Biomedicine; and the Samuel Waxman Cancer Research Foundation.

Data availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflict for publication

All authors have agreed to publish this manuscript.

Ethics approval and consent to participate

The study was approved by the Shanghai Ruijin Hospital review board with informed consent obtained in accordance with the Declaration of Helsinki. Animals were used according to the protocols approved by Shanghai Ruijin Hospital Animal Care and Use Committee.

Published online: 25 March 2021

Received: 7 October 2020 Revised: 8 February 2021 Accepted: 22 February 2021

References

1. Armitage, J. O. The aggressive peripheral T-cell lymphomas: 2017. Am. J. Hematol. 92, 706–715 (2017).
2. Marchi, E. & O’Connor, O. A. The rapidly changing landscape in mature T-cell lymphomas (MTCL) biology and management. CA Cancer J. Clin. 70, 47–70 (2020).
3. Casulo, C. et al. T-cell lymphoma: recent advances in characterization and new opportunities for treatment. J. Natl Cancer Inst. 109, https://doi.org/10.1093/jnci/djw248 (2017).
4. Ellin, F., Landstrom, J., Jerkeman, M. & Relander, T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 124, 1570–1577 (2014).
5. Zhang, J. Y. et al. Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL). Am. J. Hematol. 93, 394–400 (2018).
6. Hapgood, G. & Savage, K. J. The biology and management of systemic ana-plastic large cell lymphoma. Blood 126, 17–25 (2015).
7. Wilcox, R. A. A three-signal model of T-cell lymphoma pathogenesis. Am. J. Hematol. 91, 113–122 (2016).
8. Yang, J. & Wang, X. Role of long non-coding RNAs in lymphoma: a systematic review and clinical perspectives. Crit. Rev. Oncol/Hematol. 141, 13–22 (2019).
9. Zheng, Z. et al. MR155 sensitized β-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+ T-cells. Mol. Cancer 18, 54 (2019).
10. Yer, M. K. et al. The landscape of long non-coding RNAs in the human transcriptome. Nat. Genet. 47, 199–208 (2015).
11. Peng, W. X., Koira, P. & Ma, Y. Y. LncRNA-mediated regulation of cell signaling in cancer. Oncogene 36, 5661–5667 (2017).
12. Bhan, A., Salemani, M. & Mandai, S. S. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 77, 3965–3981 (2017).
13. Zhao, X. & Tian, X. Knockdown of long noncoding RNA HOTAIR inhibits cell growth of human lymphoma cells by upregulation of miR-148b. J. Cell. Biochem. 120, 12348–12359 (2019).
14. Ghafari-Fard, S., Esmaeili, M. & Taheri, M. Expression of non-coding RNAs in hematological malignancies. Eur. J. Pharmacol. 875, 172976 (2020).
15. Yi Ren, H. et al. Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol. Cancer 16, 174 (2017).
16. Schmitt, A. M. & Chang, H. Y. Long noncoding RNAs in cancer pathways. Cancer Cell 29, 452–465 (2016).
17. Sanchez Colle, A., Kawamura, Y., Yamamoto, Y., Takeshita, F. & Ochiya, T. Emerging roles of long non-coding RNA in cancer. Cancer Sci. 109, 2099–2100 (2018).
18. Cai, M. C. et al. CEOP/ME/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial. Genome Med. 12, 41 (2020).
19. Polyatskii, I. L., Artemyeva, A. S. & Krivolapov, Y. A. Revised WHO classification of tumors of hematopoietic and lymphoid tissues, 2017 (4th edition)/lymphoid tumors. Arkhiv Patologii 81, 59–65 (2019).
20. Xiong, J. et al. Genomic and transcriptomic characterization of natural killer T cell lymphoma: Cancer Cell 37, 403–416 (2020).
21. Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast splice aligner with low memory requirements. Nat. Methods 12, 357–366 (2015).
22. Dobin, A. et al. STAR ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
23. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
24. Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler an R package for comparing biological themes among gene clusters. Omics 16, 284–287 (2012).
25. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
26. Yan, Z. X. et al. MicroRNA1817 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma. Leukemia 28, 880–887 (2014).
27. Si, W. et al. MTA2-mediated inhibition of PTEN leads to pancreatic ductal adenocarcinoma carcinogenicity. Cell Death Dis. 10, 206 (2019).
28. Zou, J. et al. Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells. J. Hematol. Oncol. 6, 3 (2013).
29. Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1101–1108 (2008).
30. Jin, D. et al. m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDF3-mediated YAP expression and inhibiting miR-107/LATS2-mediated YAP activity in NSCLC. Mol. Cancer 19, 40 (2020).
31. Wang, Q. et al. N6-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification. Cell Death Dis. 11, 911 (2020).
32. Zhao, P. et al. Long noncoding RNA SNHG6 promotes carcinogenesis by enhancing YBX1-mediated translation of HIF1α in clear cell renal cell carcinoma. FASEB J. 35, e21160 (2021).
33. Han, M. et al. Exosome-mediated lncRNA AFAP1-AS1 promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translation. Mol. Cancer 19, 26 (2020).
34. Ramanathan, M., Porter, D. F. & Khavari, P. A. Methods to study RNA-protein interactions. Nat. Methods 16, 225–234 (2019).
35. Yao, R. W., Wang, Y. & Chen, L. Cellular functions of long noncoding RNAs. Nat. Cell Biol. 21, 542–551 (2019).
36. Anfossi, S., Babayan, A., Pantel, K. & Calin, G. A. Clinical utility of circulating non-coding RNAs - an update. Nat. Rev. Clin. Oncol. 15, 541–563 (2018).
37. Secane, J. & Gomis, R. R. TGF-β family signaling in tumor suppression and cancer progression. Cold Spring Harbor Perspect. Biol. 9, https://doi.org/10.1101/cshperspect.a022277 (2017).
38. Chang, T. P., Poloratsky, V. & Vancurova, I. Bortezomib inhibits expression of TGF-beta1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells. J. Immunol. 194, 2942–2953 (2015).
39. Holmgaard, R. B. et al. Targeting the TGFβ pathway with galunisertib, a TGFβRII small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as mono-therapy and in combination with checkpoint blockade. J. Immunother. Cancer 6, 47 (2018).
40. Santini, V. et al. Phase II study of the ALK5 inhibitor galunisertib in very low-, low-, and intermediate-risk myelodysplastic syndromes. Clin. Cancer Res. 25, 6976–6985 (2019).
41. Geuens, T., Bouthy, D. & Timmerman, V. The hnRNP family: insights into their role in health and disease. Hum. Genet. 135, 851–867 (2016).
42. Sun, Q., Hao, Q. & Prasanth, K. V. Nuclear long noncoding RNAs: key regulators of gene expression. Trends Genet. 34, 142–157 (2018).
43. Li, J., He, M., Xu, W. & Huang, S. LncRNA01354 interacting with hnRNP-D constitutively contributes to the proliferation and metastasis in colorectal cancer through activating Wnt/β-catenin signaling pathway. J. Exp. Clin. Cancer Res. 38, 161 (2019).
44. Kohno, K., Izumi, H., Uchiumi, T., Ashizuka, M. & Kuvano, M. The pleiotropic functions of the Y-box-binding protein, YB-1. BioEssays 25, 691–698 (2003).
45. Ali, M. M. et al. PAN-cancer analysis of S-phase enriched lncRNAs identifies oncogenic drivers and biomarkers. Nat. Commun. 9, 883 (2018).

Official journal of the Cell Death Differentiation Association